TOWA Pharmaceutical Co (FRA:6QC) Beneish M-Score: -2.84 (As of Jun. 26, 2026)


FRA:6QC TOWA Pharmaceutical Co Ltd FRA:6QC
86 GF Score
Price €20.40
GF Value €17.85
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is TOWA Pharmaceutical Co Beneish M-Score?

TOWA Pharmaceutical Co FRA:6QC 86 Beneish M-Score is -2.84 as of Jun. 26, 2026. GuruFocus rates FRA:6QC with a GF Score™ of 86/100 and a GF Value™ of €17.85 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 911 Drug Manufacturers companies, TOWA Pharmaceutical Co ranks better than 77.83% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.84 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for TOWA Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

FRA:6QC' s Beneish M-Score Range Over the Past 10 Years
Min: -2.84   Med: -2.4   Max: -1.47
Current: -2.84

During the past 13 years, the highest Beneish M-Score of TOWA Pharmaceutical Co was -1.47. The lowest was -2.84. And the median was -2.40.


TOWA Pharmaceutical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for TOWA Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TOWA Pharmaceutical Co Beneish M-Score Chart

TOWA Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.03 -2.37 -2.15 -2.61 -2.84

TOWA Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.61 0.00 0.00 0.00 -2.84

FRA:6QC vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, TOWA Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TOWA Pharmaceutical Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TOWA Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where TOWA Pharmaceutical Co's Beneish M-Score falls into.


FRA:6QC
86GF Score
TOWA Pharmaceutical Co Ltd FRA:6QC
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TOWA Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of TOWA Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9767+0.528 * 1.0078+0.404 * 0.6707+0.892 * 0.9262+0.115 * 0.9032
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1+4.679 * -0.052976-0.327 * 0.9846
=-2.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €345 Mil.
Revenue was €1,492 Mil.
Gross Profit was €540 Mil.
Total Current Assets was €1,457 Mil.
Total Assets was €2,591 Mil.
Property, Plant and Equipment(Net PPE) was €930 Mil.
Depreciation, Depletion and Amortization(DDA) was €124 Mil.
Selling, General, & Admin. Expense(SGA) was €0 Mil.
Total Current Liabilities was €528 Mil.
Long-Term Debt & Capital Lease Obligation was €1,069 Mil.
Net Income was €29 Mil.
Gross Profit was €0 Mil.
Cash Flow from Operations was €166 Mil.
Total Receivables was €381 Mil.
Revenue was €1,611 Mil.
Gross Profit was €588 Mil.
Total Current Assets was €1,535 Mil.
Total Assets was €2,922 Mil.
Property, Plant and Equipment(Net PPE) was €1,045 Mil.
Depreciation, Depletion and Amortization(DDA) was €125 Mil.
Selling, General, & Admin. Expense(SGA) was €0 Mil.
Total Current Liabilities was €546 Mil.
Long-Term Debt & Capital Lease Obligation was €1,284 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(344.964 / 1492.029) / (381.331 / 1610.951)
=0.231205 / 0.236712
=0.9767

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(587.855 / 1610.951) / (540.229 / 1492.029)
=0.364912 / 0.362077
=1.0078

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1457.321 + 930.197) / 2590.867) / (1 - (1534.696 + 1045.175) / 2921.765)
=0.078487 / 0.117016
=0.6707

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1492.029 / 1610.951
=0.9262

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(124.727 / (124.727 + 1045.175)) / (124.487 / (124.487 + 930.197))
=0.106613 / 0.118033
=0.9032

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 1492.029) / (0 / 1610.951)
=0 / 0
=1

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1069.315 + 528.035) / 2590.867) / ((1283.813 + 545.719) / 2921.765)
=0.616531 / 0.626174
=0.9846

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(28.618 - 0 - 165.872) / 2590.867
=-0.052976

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

TOWA Pharmaceutical Co has a M-score of -2.95 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.84 mean?
TOWA Pharmaceutical Co (FRA:6QC) has a Beneish M-Score of -2.84 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on TOWA Pharmaceutical Co and its competitors. According to the industry distribution chart, TOWA Pharmaceutical Co ranks #202 out of 911 companies in the Drug Manufacturers industry, placing it in the top 22.2%.
Is TOWA Pharmaceutical Co's Beneish M-Score too high?
TOWA Pharmaceutical Co's current Beneish M-Score is -2.84. Based on the distribution chart, TOWA Pharmaceutical Co ranks #202 out of 911 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, TOWA Pharmaceutical Co has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does TOWA Pharmaceutical Co's Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, TOWA Pharmaceutical Co ranks #202 out of 911 companies for Beneish M-Score. This places TOWA Pharmaceutical Co in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on TOWA Pharmaceutical Co and its competitors. TOWA Pharmaceutical Co's current Beneish M-Score is -2.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TOWA Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, TOWA Pharmaceutical Co (FRA:6QC) is currently considered Modestly Overvalued. The stock's GF Value™ is €17.85, compared to a current price of €20.40 — trading 14.3% above its estimated fair value. The current Beneish M-Score is -2.84. TOWA Pharmaceutical Co's overall GF Score™ is 86/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For TOWA Pharmaceutical Co (FRA:6QC), the current Beneish M-Score is -2.84 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TOWA Pharmaceutical Co (FRA:6QC) Overvalued in 2026?

Based on GuruFocus' analysis, TOWA Pharmaceutical Co stock appears to be overvalued. The current stock price of €20.40 is trading 14.3% above its estimated GF Value™ of €17.85. GuruFocus considers TOWA Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for FRA:6QC:

  • Beneish M-Score: -2.84
  • GF Value™: €17.85 vs. price of €20.40 (14.3% above fair value)
  • GF Score™: 86/100 with 5 warning signs

No single metric tells the full story. See the FRA:6QC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TOWA Pharmaceutical Co Business Description

Other Exchanges 4553:Japan
Address 2-11, Shinbashi-cho, Kadoma, Osaka, JPN, 571-8580
TOWA Pharmaceutical Co Ltd is a Japan based pharmaceutical company engaged in research and development, production, and marketing of generic drugs. It also provides drug consulting services for patients and their families and relatives. It organizes academic seminars for medical professionals and posts articles in journals. It participates in training for pharmacists. The company has three main plants in operation namely Osaka plant, Okayama plant, and Yamagata plant. Towa has offers more than 500 drugs to meet the diverse therapeutic requirements including lifestyle related diseases such as hypertension and diabetes, digestive system diseases, nervous system diseases and allergic diseases, vitamins and antibiotics.
86GF Score

Get the complete analysis for FRA:6QC

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.40
Price
€17.85
GF Value